Genomic Health, Inc. (NASDAQ:GHDX) – Equities researchers at Jefferies Group reduced their FY2017 earnings per share estimates for shares of Genomic Health in a research note issued on Thursday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings of ($0.09) per share for the year, down from their previous forecast of $0.01. Jefferies Group has a “Hold” rating and a $34.00 price objective on the stock.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/jefferies-group-comments-on-genomic-health-inc-s-fy2017-earnings-ghdx/1703912.html.

GHDX has been the topic of a number of other reports. Zacks Investment Research upgraded Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Cowen and Company restated a “hold” rating and set a $34.00 target price on shares of Genomic Health in a report on Friday, September 1st. BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Piper Jaffray Companies restated a “hold” rating and set a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Finally, ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $32.00.

Shares of Genomic Health (NASDAQ:GHDX) opened at $28.38 on Monday. Genomic Health has a 1 year low of $26.37 and a 1 year high of $34.02.

Institutional investors and hedge funds have recently modified their holdings of the company. Wetherby Asset Management Inc. lifted its stake in Genomic Health by 3.7% in the second quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock valued at $290,000 after buying an additional 317 shares during the period. Dubuque Bank & Trust Co. lifted its stake in Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after buying an additional 379 shares during the period. Parametric Portfolio Associates LLC lifted its stake in Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after buying an additional 441 shares during the period. Bank of New York Mellon Corp lifted its stake in Genomic Health by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock valued at $2,789,000 after buying an additional 500 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in Genomic Health by 3.4% in the second quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after buying an additional 520 shares during the period. 89.13% of the stock is currently owned by institutional investors and hedge funds.

In other news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total transaction of $159,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Insiders have sold 21,379 shares of company stock worth $676,131 in the last 90 days. Company insiders own 46.20% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.